Walking one hour per day and the derived neutrophil-to-lymphocyte ratio are associated with outcome in palliative second-line immunotherapy for patients with recurrent and/or metastatic squamous cell carcinoma of head and neck
-
Published:2024-11
Issue:6
Volume:90
Page:101493
-
ISSN:1808-8694
-
Container-title:Brazilian Journal of Otorhinolaryngology
-
language:en
-
Short-container-title:Brazilian Journal of Otorhinolaryngology
Author:
Caballero-Borrego MiguelORCID,
Piedra AidaORCID,
Gallego ÓscarORCID,
López-Pousa AntonioORCID,
Castillo PaolaORCID,
Navarrete PilarORCID,
Prat AlbaORCID,
Grau Juan J.ORCID
Reference44 articles.
1. Global Cancer Statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries;Sung;CA Cancer J Clin.,2021
2. Follow-up in head and neck cancer: do more does it mean do better? A systematic review and our proposal based on our experience;Denaro;Clin Exp Otorhinolaryngol.,2016
3. NCCN guidelines® insights head and neck cancers, version 2.2017 featured updates to the NCCN guidelines;Adelstein;JNCCN J Natl Compr Cancer Netw,2017
4. Immune checkpoint inhibitors in head and neck squamous cell carcinoma: a systematic review of phase-3 clinical trials;Poulose;World J Clin Oncol.,2022
5. Pembrolizumab versus methotrexate, docetaxel, or cetuximab for recurrent or metastatic head-and-neck squamous cell carcinoma (KEYNOTE-040): a randomised, open-label, phase 3 study;Cohen;Lancet,2019